Another study supported that CDK4/6i remarkably strengthened tumor immunogenicity and provided a theoretical basis for combination therapy with CDK4/6 inhibitors and immunotherapies as anticancer treatments [14]. The gene discussed is CDK4; the disease is neoplasm.